Goldman Sachs’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.01M | Sell |
3,602,827
-1,103,610
| -23% | -$1.52M | ﹤0.01% | 3690 |
|
|
2025
Q4 | $7.58M | Buy |
4,706,437
+2,938,624
| +166% | +$6.15M | ﹤0.01% | 3351 |
|
|
2025
Q3 | $4.83M | Sell |
1,767,813
-2,166,189
| -55% | -$7.21M | ﹤0.01% | 3681 |
|
|
2025
Q2 | $14.3M | Buy |
3,934,002
+1,209,563
| +44% | +$3.32M | ﹤0.01% | 2424 |
|
|
2025
Q1 | $5.23M | Buy |
2,724,439
+1,722,245
| +172% | +$3.52M | ﹤0.01% | 3304 |
|
|
2024
Q4 | $1.9M | Buy |
1,002,194
+516,925
| +107% | +$898K | ﹤0.01% | 4319 |
|
|
2024
Q3 | $641K | Buy |
485,269
+136,351
| +39% | +$182K | ﹤0.01% | 4912 |
|
|
2024
Q2 | $356K | Sell |
348,918
-1,064,735
| -75% | -$1.32M | ﹤0.01% | 5008 |
|
|
2024
Q1 | $2.59M | Buy |
1,413,653
+1,342,452
| +1,885% | +$2.15M | ﹤0.01% | 3666 |
|
|
2023
Q4 | $4.83M | Buy |
+71,201
| New | +$72.6K | ﹤0.01% | 3189 |
|
|
2023
Q3 | – | Sell |
-18,273
| Closed | -$16.7K | – | 5518 |
|
|
2023
Q2 | $16.7K | Sell |
18,273
-49,571
| -73% | -$47.8K | ﹤0.01% | 5561 |
|
|
2023
Q1 | $38K | Buy |
67,844
+52,516
| +343% | +$40.1K | ﹤0.01% | 5589 |
|
|
2022
Q4 | $8.84K | Sell |
15,328
-448,482
| -97% | -$141K | ﹤0.01% | 5762 |
|
|
2022
Q3 | $147K | Buy |
463,810
+122,264
| +36% | +$48K | ﹤0.01% | 5584 |
|
|
2022
Q2 | $0 | Sell |
341,546
-559,421
| -62% | -$235K | ﹤0.01% | 6428 |
|
|
2022
Q1 | $647K | Sell |
900,967
-1,246,196
| -58% | -$2.67M | ﹤0.01% | 5160 |
|
|
2021
Q4 | $4.85M | Buy |
2,147,163
+1,632,905
| +318% | +$4.45M | ﹤0.01% | 3441 |
|
|
2021
Q3 | $1.48M | Sell |
514,258
-2,593,278
| -83% | -$7.4M | ﹤0.01% | 4447 |
|
|
2021
Q2 | $11.8M | Buy |
3,107,536
+328,849
| +12% | +$1.11M | ﹤0.01% | 2538 |
|
|
2021
Q1 | $9.41M | Sell |
2,778,687
-823,475
| -23% | -$2.97M | ﹤0.01% | 2620 |
|
|
2020
Q4 | $10.1M | Buy |
3,602,162
+2,150,016
| +148% | +$6.28M | ﹤0.01% | 2464 |
|
|
2020
Q3 | $3.65M | Buy |
1,452,146
+314,613
| +28% | +$2.76M | ﹤0.01% | 3131 |
|
|
2020
Q2 | $15.4M | Buy |
1,137,533
+365,281
| +47% | +$3.78M | ﹤0.01% | 1892 |
|
|
2020
Q1 | $5.85M | Buy |
772,252
+23,866
| +3% | +$186K | ﹤0.01% | 2519 |
|
|
2019
Q4 | $4.73M | Buy |
748,386
+439,972
| +143% | +$2.09M | ﹤0.01% | 3012 |
|
|
2019
Q3 | $1.21M | Buy |
308,414
+53,468
| +21% | +$229K | ﹤0.01% | 3906 |
|
|
2019
Q2 | $1.23M | Sell |
254,946
-106,327
| -29% | -$605K | ﹤0.01% | 3859 |
|
|
2019
Q1 | $2.96M | Sell |
361,273
-7,230
| -2% | -$49.6K | ﹤0.01% | 3344 |
|
|
2018
Q4 | $2.04M | Buy |
368,503
+244,878
| +198% | +$1.92M | ﹤0.01% | 3524 |
|
|
2018
Q3 | $1.09M | Sell |
123,625
-184,354
| -60% | -$1.65M | ﹤0.01% | 4004 |
|
|
2018
Q2 | $3.07M | Sell |
307,979
-473,478
| -61% | -$4.74M | ﹤0.01% | 3307 |
|
|
2018
Q1 | $7.45M | Buy |
781,457
+97,537
| +14% | +$1.36M | ﹤0.01% | 2592 |
|
|
2017
Q4 | $10.2M | Buy |
683,920
+43,923
| +7% | +$728K | ﹤0.01% | 2449 |
|
|
2017
Q3 | $12.6M | Buy |
639,997
+348,107
| +119% | +$5.35M | ﹤0.01% | 2372 |
|
|
2017
Q2 | $4.2M | Buy |
291,890
+242,613
| +492% | +$3.08M | ﹤0.01% | 3210 |
|
|
2017
Q1 | $453K | Buy |
49,277
+608
| +1% | +$5.93K | ﹤0.01% | 5121 |
|
|
2016
Q4 | $507K | Buy |
48,669
+30,513
| +168% | +$263K | ﹤0.01% | 5053 |
|
|
2016
Q3 | $164K | Buy |
18,156
+4,376
| +32% | +$37.2K | ﹤0.01% | 5952 |
|
|
2016
Q2 | $103K | Sell |
13,780
-447
| -3% | -$3.9K | ﹤0.01% | 6114 |
|
|
2016
Q1 | $128K | Buy |
14,227
+2,616
| +23% | +$21.2K | ﹤0.01% | 5933 |
|
|
2015
Q4 | $150K | Buy |
+11,611
| New | +$118K | ﹤0.01% | 5908 |
|
|
2015
Q3 | – | Sell |
-17,616
| Closed | -$181K | – | 7256 |
|
|
2015
Q2 | $181K | Buy |
+17,616
| New | +$150K | ﹤0.01% | 6218 |
|
Other funds holding AKBA
VCM
VPM
Goldman Sachs's AKBA Position: Q1 2026 in Review
Goldman Sachs reduced its Akebia Therapeutics (AKBA) stake by 23% in Q1 2026, selling an estimated $1.52M and leaving 3,602,827 shares worth $5.01M. The position accounts for ﹤0.01% of the portfolio, ranked #3690.
Goldman Sachs first reported a position in AKBA in Q2 2015 and has held it in 42 quarters since. The position peaked at $15.4M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Goldman Sachs held 3,602,827 shares of Akebia Therapeutics worth $5.01M as of Q1 2026.
- Goldman Sachs sold 1,103,610 Akebia Therapeutics shares in Q1 2026, an estimated $1.52M.
- Akebia Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3690 holding.
- Goldman Sachs first reported a position in Akebia Therapeutics in Q2 2015 and has held it in 42 quarters since.
- Goldman Sachs's Akebia Therapeutics position peaked at $15.4M in Q2 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.